AbbVie

In the trial study, evaluating the efficacy and safety of Upadacitinib in adult patients with nr-axSpA, Upadacitinib met its…

The US Food and Drug Administration's boxed warnings on the labels of Rinvoq , Xeljanz and Olumiant flags the risk of…

Every year, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS) in the US, and there remains a high…

Bayer, Ferring International and AbbVie were among the most highly active sponsors with 21, 11 and seven trials, respectively

The growth is drive by an increasing number of aesthetic procedures, technological advancements, growing urban population,…

The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029

The approval is primarily based on the results of two Phase III studies, VIALE-A and VIALE-C

Johnson & Johnson maintained its top position with MCap growth of 7.2 per cent on a QoQ basis

AbbVie will provide $30 million over three years

I-SPY COVID will evaluate the impact of cenicriviroc, otezla, and firazyr on inflammatory response in severely ill, hospitalised…